Aquestive Therapeutics (AQST) Revenue & Revenue Breakdown
Aquestive Therapeutics Revenue Highlights
Latest Revenue (Y)
$50.58M
Latest Revenue (Q)
$20.10M
Main Segment (Y)
Manufacture and Supply Revenue
Main Geography (Y)
UNITED STATES
Aquestive Therapeutics Revenue by Period
Aquestive Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $50.58M | 6.09% |
| 2022-12-31 | $47.68M | -6.20% |
| 2021-12-31 | $50.83M | 10.87% |
| 2020-12-31 | $45.85M | -12.85% |
| 2019-12-31 | $52.61M | -21.98% |
| 2018-12-31 | $67.43M | 0.77% |
| 2017-12-31 | $66.92M | 29.22% |
| 2016-12-31 | $51.78M | - |
Aquestive Therapeutics generated $50.58M in revenue during NA 2023, up 6.09% compared to the previous quarter, and up 75.02% compared to the same period a year ago.
Aquestive Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $20.10M | 66.76% |
| 2024-03-31 | $12.05M | -8.73% |
| 2023-12-31 | $13.21M | 1.57% |
| 2023-09-30 | $13.00M | -1.80% |
| 2023-06-30 | $13.24M | 18.92% |
| 2023-03-31 | $11.13M | 4.23% |
| 2022-12-31 | $10.68M | -6.81% |
| 2022-09-30 | $11.46M | -13.58% |
| 2022-06-30 | $13.27M | 8.11% |
| 2022-03-31 | $12.27M | 10.76% |
| 2021-12-31 | $11.08M | -16.63% |
| 2021-09-30 | $13.29M | -13.41% |
| 2021-06-30 | $15.35M | 37.97% |
| 2021-03-31 | $11.12M | 55.57% |
| 2020-12-31 | $7.15M | -13.45% |
| 2020-09-30 | $8.26M | -61.89% |
| 2020-06-30 | $21.68M | 147.29% |
| 2020-03-31 | $8.77M | -46.62% |
| 2019-12-31 | $16.42M | 32.22% |
| 2019-09-30 | $12.42M | 11.58% |
| 2019-06-30 | $11.13M | -11.98% |
| 2019-03-31 | $12.64M | -24.85% |
| 2018-12-31 | $16.82M | 26.81% |
| 2018-09-30 | $13.27M | -4.75% |
| 2018-06-30 | $13.93M | -40.51% |
| 2018-03-31 | $23.41M | 91.97% |
| 2017-12-31 | $12.20M | -55.08% |
| 2017-09-30 | $27.15M | 143.64% |
| 2017-06-30 | $11.14M | -32.21% |
| 2017-03-31 | $16.44M | - |
Aquestive Therapeutics generated $20.10M in revenue during Q2 2024, up 66.76% compared to the previous quarter, and up 180.52% compared to the same period a year ago.
Aquestive Therapeutics Revenue Breakdown
Aquestive Therapeutics Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|---|---|
| Co-Development and Research Fees | $1.40M | $1.29M | $1.64M | $1.26M | $4.04M |
| License and Royalty Revenue | $5.38M | $2.35M | $5.38M | $14.05M | $6.96M |
| Manufacture and Supply Revenue | $43.80M | $36.38M | $35.31M | $24.88M | $38.74M |
| Proprietary Product Sales | - | $7.66M | $8.51M | $5.65M | $2.87M |
| Royalty | - | $-916.00K | $-1.10M | - | - |
Aquestive Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 23: Manufacture and Supply Revenue (86.60%), License and Royalty Revenue (10.63%), and Co-Development and Research Fees (2.77%).
Quarterly Revenue by Product
| Product/Service | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| License and Royalty Revenue | $1.13M | $1.87M | $1.10M | $1.48M | $919.00K | $917.00K | $376.00K | $552.00K | $506.00K | $380.00K | $328.00K | $2.36M | $373.00K | $328.00K | $12.93M | $426.00K | $557.00K | $1.36M | $424.00K | - |
| Co-Development and Research Fees | $403.00K | $335.00K | $490.00K | $124.00K | $453.00K | $254.00K | $395.00K | $241.00K | $403.00K | $218.00K | $523.00K | $456.00K | $394.00K | $1.18M | - | - | - | - | - | - |
| Manufacture and Supply Revenue | $10.52M | $11.00M | $11.41M | $11.64M | $9.76M | $8.92M | $8.41M | $9.87M | $9.17M | $7.69M | $10.45M | $10.66M | $6.51M | $4.80M | $5.90M | $7.26M | $6.92M | $14.00M | $9.15M | $8.91M |
| Proprietary Product Sales | - | - | - | - | - | $589.00K | $2.28M | $2.60M | $2.19M | $2.79M | $1.99M | $1.91M | $1.58M | $682.00K | - | - | - | - | - | - |
| Royalty | - | - | - | - | - | $-13.00K | $-25.00K | - | - | - | - | - | - | - | - | - | - | - | - | - |
Aquestive Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Mar 24: Manufacture and Supply Revenue (87.26%), License and Royalty Revenue (9.39%), and Co-Development and Research Fees (3.34%).
Aquestive Therapeutics Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|---|---|
| UNITED STATES | $37.10M | $39.92M | $42.86M | - | - |
| Non-US | $13.48M | $7.76M | $7.97M | $4.89M | $4.32M |
| United States | - | - | - | $40.96M | $48.29M |
Aquestive Therapeutics's latest annual revenue breakdown by geography, as of Dec 23: UNITED STATES (73.35%), and Non-US (26.65%).
Quarterly Revenue by Country
| Country | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Dec 20 | Dec 19 | Dec 18 | Sep 18 | Jun 18 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-US | $1.63M | $1.47M | $3.11M | $5.93M | $2.97M | $2.18M | $2.38M | $2.01M | $1.19M | $1.71M | $2.76M | $2.24M | $1.69M | $1.81M | - | - | - |
| UNITED STATES | $10.43M | $11.73M | $9.89M | $7.31M | $8.16M | $8.51M | $9.08M | $11.26M | $11.08M | $9.37M | $10.53M | $13.11M | - | - | - | - | - |
| United States | - | - | - | - | - | - | - | - | - | - | - | - | $5.46M | $14.61M | $15.51M | $12.48M | $13.38M |
Aquestive Therapeutics's latest quarterly revenue breakdown by geography, as of Mar 24: UNITED STATES (86.51%), and Non-US (13.49%).
Aquestive Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| ALKS | Alkermes | $1.66B | $399.13M |
| LNTH | Lantheus | $1.30B | $394.09M |
| AMPH | Amphastar Pharmaceuticals | $593.24M | $182.39M |
| ANIP | ANI Pharmaceuticals | $486.82M | $138.04M |
| IRWD | Ironwood Pharmaceuticals | $442.74M | $94.40M |
| ORGO | Organogenesis | $433.14M | $130.23M |
| EGRX | Eagle Pharmaceuticals | $316.61M | $64.65M |
| DVAX | Dynavax | $232.28M | $73.80M |
| LFCR | Lifecore Biomedical | $103.27M | $35.70M |
| ALIM | Alimera Sciences | $80.75M | $23.01M |
| AQST | Aquestive Therapeutics | $50.58M | $20.10M |
| AGRX | Agile Therapeutics | $19.59M | $5.58M |
| GHSI | Guardion Health Sciences | $12.25M | $36.35K |
| EVOK | Evoke Pharma | $5.18M | $1.74M |
| ADMP | Adamis Pharmaceuticals | $4.76M | $9.06M |
| ACRX | Talphera | $651.00K | $117.00K |
| LSDI | Lucy Scientific Discovery | $7.05K | $9.68K |
| SHPH | Shuttle Pharmaceuticals | - | - |
AQST Revenue FAQ
What is Aquestive Therapeutics’s yearly revenue?
Aquestive Therapeutics's yearly revenue for 2023 was $50.58M, representing an increase of 6.09% compared to 2022. The company's yearly revenue for 2022 was $47.68M, representing a decrease of -6.20% compared to 2021. AQST's yearly revenue for 2021 was $50.83M, representing an increase of 10.87% compared to 2020.
What is Aquestive Therapeutics’s quarterly revenue?
Aquestive Therapeutics's quarterly revenue for Q2 2024 was $20.1M, a 66.76% increase from the previous quarter (Q1 2024), and a 51.79% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $12.05M, a -8.73% decrease from the previous quarter (Q4 2023), and a 8.25% increase year-over-year (Q1 2023). AQST's quarterly revenue for Q4 2023 was $13.21M, a 1.57% increase from the previous quarter (Q3 2023), and a 23.63% increase year-over-year (Q4 2022).
What is Aquestive Therapeutics’s revenue growth rate?
Aquestive Therapeutics's revenue growth rate for the last 3 years (2021-2023) was -0.49%, and for the last 5 years (2019-2023) was -3.85%.
What are Aquestive Therapeutics’s revenue streams?
Aquestive Therapeutics's revenue streams in c 23 are Co-Development and Research Fees, License and Royalty Revenue, and Manufacture and Supply Revenue. Co-Development and Research Fees generated $1.4M in revenue, accounting 2.77% of the company's total revenue, up 8.43% year-over-year. License and Royalty Revenue generated $5.38M in revenue, accounting 10.63% of the company's total revenue, up 128.67% year-over-year. Manufacture and Supply Revenue generated $43.8M in revenue, accounting 86.60% of the company's total revenue, up 20.42% year-over-year.
What is Aquestive Therapeutics’s main source of revenue?
For the fiscal year ending Dec 23, the largest source of revenue of Aquestive Therapeutics was Manufacture and Supply Revenue. This segment made a revenue of $43.8M, representing 86.60% of the company's total revenue.